If you searched for KLTO stock sometime in mid-2025, you probably saw a chart that looked like a heart monitor spike and then a long, slow descent. That kind of dramatic price movement tends to attract attention, and for good reason. The story behind that ticker is genuinely unusual, involving an 800% single-day surge, a shift away from neuroscience entirely, and a company that now goes by a completely different name with a completely different business model.
Whether you are researching what happened to your investment, trying to understand where the company stands today, or simply following one of the odder pivots in recent small-cap history, here is what you need to know.
What Was Klotho Neurosciences?
Klotho Neurosciences, Inc. was a small biopharmaceutical company headquartered in Omaha, Nebraska. It traded on the Nasdaq Capital Market under the ticker KLTO and focused on developing gene therapy and cell-based treatments for neurodegenerative diseases, as well as cancer and cardiovascular conditions.
The company was firmly in early-stage territory. Like many small biotechs, it was not profitable. Negative earnings are standard for companies that are still funding research rather than generating revenue from approved products. Its market capitalization fluctuated between roughly $17 million and $56 million depending on when you looked, placing it firmly in the micro-cap category.
The Science Behind the Name
The company’s name referenced Klotho, a protein associated with longevity and cognitive function that has been the subject of growing scientific interest. Researchers have explored its potential role in slowing age-related decline, which gave the company a compelling narrative at a time when anti-aging science was attracting serious investment and media attention.
The 800% Spike: What Happened in June 2025
In June 2025, KLTO shares surged approximately 800% in a single trading session. That number is not a typo. The trigger was the release of positive early-stage research results related to anti-aging gene therapy, the kind of headline that, in the right market environment, can send a small biotech into a frenzy.
To put the price range in perspective: the stock’s 52-week range stretched from a low of around $0.11 to a high of $3.91. That is an extraordinary spread for any stock, let alone one with a market cap measured in the tens of millions. For investors who timed it correctly, the returns were spectacular. For those who bought near the peak, the experience was considerably less pleasant.
Understanding the Volatility
Moves like this are not uncommon in small-cap biotech. When a company with a low share price and limited trading volume receives a positive headline, especially one tied to a hot research area like anti-aging or gene therapy, retail investor interest can flood in quickly, pushing the price far beyond what fundamentals would normally support. The subsequent pullback is equally sharp.
That pattern played out here. The spike was real, but so was the correction that followed.
The Pivot: From Biotech to Mining
Here is where the story takes its most unexpected turn. In March 2026, the company announced it was changing its name to Greenland Mines Ltd and rebranding its ticker from KLTO to GRML. The reason was a strategic shift driven by the acquisition of mining assets in Greenland, with a new focus on critical minerals, specifically gold, palladium, and platinum.
This is not a subtle adjustment to an existing business plan. It is a complete reinvention. The company that was developing gene therapies for Alzheimer’s and cancer is now positioning itself as a natural resources company in one of the world’s most geopolitically significant mining regions. Greenland has attracted considerable attention from multiple governments and private investors in recent years due to its deposits of rare earth elements and precious metals.
As of 2026, GRML shares were trading in the $0.30 to $0.40 range, still a penny stock by definition, still unprofitable, and now carrying an additional layer of uncertainty that comes with any company attempting to rebuild its identity from scratch in a completely different industry.
Key Risks Worth Understanding
Anyone evaluating this company whether under its old ticker or the new one should weigh a few straightforward facts. The share price is below $1, which puts it in penny stock territory and means price swings can be extreme in both directions. The company has not been profitable under either business model. The pivot from biopharmaceuticals to mining adds genuine strategic uncertainty, since neither management team nor investor base necessarily has deep expertise in both areas. There is also a Nasdaq compliance consideration, as stocks trading consistently below $1 face potential delisting risk under exchange rules.
None of this means the company cannot succeed. Early-stage companies in both biotech and mining regularly trade at low prices before eventually delivering returns. But the risk profile here is high by any measure.
The Bottom Line
KLTO stock was a brief but memorable chapter in the small-cap biotech world, a tiny company with an intriguing scientific premise that experienced one of the more dramatic single-day price moves of 2025. That ticker no longer exists, replaced by GRML and a business pivot that few investors would have predicted when Klotho Neurosciences first listed on Nasdaq.
Whether the mining strategy ultimately pays off remains to be seen. For now, it represents a high-risk, high-uncertainty bet on a company that has already shown it is willing to reinvent itself entirely. That kind of flexibility can be a strength or a warning sign depending on what happens next.
Discover Also DARE Stock: What Investors Need to Know About Daré Bioscience
Discover more from VyvyDaily
Subscribe to get the latest posts sent to your email.
